SCHEMBL13034922

SCHEMBL13034922

CCOc1ccc(C(NC(=O)CN)c2ccc(OC)cc2OC)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.56
▸ KMT2A Q03164 6/20 0.49
▸ MEN1 O00255 4/20 0.49
▸ TSHR P16473 3/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ ADORA3 P0DMS8 1/20 0.48
▸ ADRA1A P35348 1/20 0.48
▸ MAPT P10636 2/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ ACACB O00763 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ POLB P06746 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ HTT P42858 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ HSP90AA1 P07900 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13035855 0.88 LMNA (0.72) LMNAKMT2AMEN1TSHRMAPT
SCHEMBL13298385 0.87 LMNA (0.53) LMNAKMT2AMEN1TSHRMAPT
SCHEMBL13035853 0.84 LMNA (0.45) LMNAKMT2AMEN1TSHRCYP1A2
SCHEMBL13034931 0.82 LMNA (0.44) LMNAKMT2AMEN1TSHRCYP1A2
SCHEMBL13635154 0.82 LMNA (0.47) LMNAKMT2AMEN1TSHRCYP1A2
SCHEMBL13298384 0.80 LMNA (0.42) LMNAKMT2AMEN1TSHRCYP1A2
SCHEMBL13635156 0.80 LMNA (0.45) LMNAKMT2AMEN1TSHRMAPT
SCHEMBL14205323 0.79 LMNA (0.49) LMNAKMT2AMEN1TSHRMAPT
SCHEMBL14381016 0.79 LMNA (0.50) LMNAKMT2AMEN1TSHRMAPT
SCHEMBL4198027 0.79 SLC6A9 (0.56) LMNAKMT2AMEN1TSHRACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286365-A1 PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME AMYLIN PHARMACEUTICALS, INC. (US) 2010-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286365-A1 PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME DNPEP, PEPD, VIP LMNA 2206/4885KMT2A 2595/4885MEN1 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback